98%
921
2 minutes
20
Neurofibromatosis type 1 (NF1) is an autosomal dominant hereditary disorder. The pathogenesis of NF1 is suggested to be an alteration of the gene, which normally functions as a tumor suppressor. A mutation of causes the development of viable tumors in various sites. On the other hand, the synchronous manifestation of a gastrointestinal stromal tumor (GIST) and neuroendocrine tumor (NET) in the background of NF1 is extremely rare. This paper reports three cases treated with surgical intervention along with the long-term follow-up results. Three patients showed synchronous ampullary NET and GIST in association with NF1 supported by postoperative histopathologic analysis. Surgical treatments, such as pancreatoduodenectomy and local excision were applied. No recurrence occurred during the postoperative follow-up period of 10, 9, and 2.7 years. Synchronous GIST and NET in the background of NF1 is extremely rare, but the possible coexistence of other tumors in NF1 patients is relatively higher than that in the general population. Furthermore, both NETs and GISTs occurring in NF1 patients tend to be smaller in size compared to that in the general population. Therefore, when NF1 patients present with vague abdominal discomfort, close attention must be paid to identifying the coexistence of other neoplasms.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4166/kjg.2019.74.4.227 | DOI Listing |
Cancer
September 2025
Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
Background: Immune checkpoint inhibitors (ICIs) in unselected sarcomas yield limited response rates and tumor control. Long-term responders have however been reported, suggesting a critical challenge in refining patient selection, by identifying reliable predictive factors for response.
Methods: The authors conducted a multicenter, retrospective study of patients with advanced sarcomas treated with ICIs in six French reference sarcoma centers.
Cancer Diagn Progn
September 2025
Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
Background/aim: Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of multiple tumors, including plexiform neurofibromas (PNFs), which often affect the craniofacial region and cause significant functional and aesthetic impairments. This report presents long-term surgical management of a patient with hemifacial diffuse PNF, complicated by the emergence of a rapidly enlarging midfacial tumor.
Case Report: The patient was treated for hemifacial invasive diffuse plexiform neurofibroma.
Front Pharmacol
August 2025
Biochemistry, Pharmacology and Newborn Screening Unit, Central Laboratory of Analysis, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of plexiform neurofibromas (PNs), benign yet potentially debilitating tumors with limited treatment options. Selumetinib, a selective MEK1/2 inhibitor, has emerged as a targeted therapy for symptomatic, inoperable PNs in pediatric NF1 patients. Individual variability in drug metabolism, largely influenced by CYP450-mediated pathways, can affect treatment response.
View Article and Find Full Text PDFJ Craniofac Surg
September 2025
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, P.R. China.
Objective: This study summarized the application effect and clinical experience of multimodal intraoperative neurophysiological monitoring (IONM) technology in the surgery of neurofibromatosis type 1 (NF1)-related craniofacial tumors.
Materials And Methods: A retrospective study was conducted on NF1 patients who were admitted between January 2019 and December 2024 and treated with craniofacial tumor resection surgery assisted by multimodal IONM technology. Data from this study were analyzed regarding sex, age at surgery, surgical procedures, IONM parameters, preoperative and postoperative symptoms, follow-up period, as well as oncological outcome.
Clin Neurophysiol
August 2025
Department of Neurology, Erasmus MC Cancer Institute, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.
Objective: To explore the value of high resolution nerve ultrasound (HRUS) and nerve conduction studies (NCS) in screening for plexiform neurofibromas (PNs) in neurofibromatosis type 1 (NF1). METHODS: Adult patients with NF1 were eligible. Patients were divided into two groups: with peripheral nervous system related symptoms (PNS group) and without PNS-related symptoms (non-PNS group).
View Article and Find Full Text PDF